Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.43 |
| ▸ | FNTB | P49356 | 8/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633226 | 0.92 | NPY1R (0.42) | FNTAFNTBPGGT1BNPY1RNPY2R | |
| SCHEMBL29558318 | 0.92 | FNTA (0.47) | FNTAFNTBPGGT1BAPLNRNPY1R | |
| SCHEMBL31107069 | 0.91 | FNTA (0.47) | FNTAFNTBOPRM1OPRD1PGGT1B | |
| SCHEMBL29531463 | 0.89 | OPRD1 (0.46) | OPRM1OPRD1NPY1RNPY2RNPY4R | |
| SCHEMBL30843955 | 0.89 | OPRD1 (0.46) | OPRM1OPRD1NPY1RNPY2RNPY4R | |
| SCHEMBL30445405 | 0.89 | FNTA (0.44) | FNTAFNTBPGGT1B | |
| SCHEMBL30629003 | 0.89 | NPY1R (0.46) | FNTAFNTBPGGT1BNPY1RNPY2R | |
| SCHEMBL30445513 | 0.87 | CALCR (0.45) | FNTAFNTBPGGT1BAPLNRBACE1 | |
| SCHEMBL29377155 | 0.87 | FNTA (0.49) | FNTAFNTBPGGT1BBACE1 | |
| SCHEMBL29630605 | 0.84 | FNTA (0.41) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | FNTA 1639/4885FNTB 208/4885OPRM1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.